Stifel Financial’s Spyre Therapeutics SYRE Stock Holding History

Stifel Financial’s Portfolio SYRE Stock Details SYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$267K	Buy	+3,011	New	+$220K	﹤0.01%	3341

Other funds holding SYRE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Stifel Financial's SYRE Position: Q2 2026 in Review

Stifel Financial opened a new position in Spyre Therapeutics (SYRE) in Q2 2026: 3,011 shares worth $267K. The stake represents ﹤0.01% of the portfolio and ranks #3341 among its holdings.

265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

Stifel Financial held 3,011 shares of Spyre Therapeutics worth $267K as of Q2 2026.
Spyre Therapeutics was a new Stifel Financial position in Q2 2026.
Spyre Therapeutics made up ﹤0.01% of Stifel Financial's portfolio in Q2 2026, its #3341 holding.
265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Stifel Financial's 13F filing for Q2 2026, filed 12 Aug 2026.